Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction

This study has been terminated.
(Enrollment rate was slower than anticipated.)
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Cady, Roger, M.D.
ClinicalTrials.gov Identifier:
NCT01053507
First received: January 19, 2010
Last updated: January 28, 2014
Last verified: January 2014

January 19, 2010
January 28, 2014
May 2010
November 2012   (final data collection date for primary outcome measure)
  • Headache Days [ Time Frame: Day 0, Day +30 ] [ Designated as safety issue: No ]
    Change in number of headache days at Day 0 vs. Day +30 in Treximet arm vs. Placebo arm.
  • Associated Headache Symptoms [ Time Frame: Day 0, Day +30 ] [ Designated as safety issue: No ]
    Change in number of associated headache symptoms at Day 0 vs. Day +30 in Treximet arm vs. Placebo arm.
  • Headache Days [ Time Frame: Day 0, Day +30 ] [ Designated as safety issue: No ]
  • Associated headache symptoms [ Time Frame: Day 0, Day +30 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01053507 on ClinicalTrials.gov Archive Site
  • Mental Efficiency Workload Test (MEWT) Performance Index [ Time Frame: Day 0, Day +30 ] [ Designated as safety issue: No ]
  • Headache Impact Test-6 (HIT-6) Score [ Time Frame: Day 0, Day +30 ] [ Designated as safety issue: No ]
  • Migraine Specific Quality of Life Questionnaire (MSQ) [ Time Frame: Day 0, Day +30 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction

This study will evaluate the effectiveness of Treximet when taken for post traumatic headache by measuring any change in the number of headache days or any change in a subject's ability to think following treatment with study medication. Eligible subjects will complete 3 visits. Following Visit 1, subjects will treat with their usual medication and document headache symptoms and therapy in a Headache Diary. After 30 days, subjects will return for Visit 2 and be randomized (like the flip of a coin) to receive Treximet or matching placebo to treat at the same time each day. Treximet will be provided to treat any headache that occurs. Subjects will complete a daily Diary. After 30 days, subjects will exit the study at Visit 3.

Subjects will be enrolled at 3 investigative sites. At Visit 1, a medical, headache, and medication history will be collected and a physical and neurological exam with vital signs will be performed. An ECG will be completed if one has not been completed in the previous 6 months. Subjects will be administered a series of psychological tests to help the study doctor decide whether or not a subject is eligible. The Headache Impact Test-6 and Migraine Specific Quality of Life Questionnaire will be completed at each visit. During a 30-day Baseline Period, subjects will treat with their usual medication and complete a daily Diary documenting headache symptoms and treatment. At Visits 2 and 3 subjects will complete the Mental Efficiency Workload Test and Migraine Early Warning Tool. Following randomization at Visit 2, subjects will treat daily for 30 days with Treximet or a matching placebo. Subjects will be provided with Treximet for rescue of any persisting or recurring headache. During the Treatment Period, subjects will complete a daily Diary reporting headache symptoms and response to treatment. After the 30-day Treatment Period, subjects will exit the study at Visit 3 .

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Post-Traumatic Headache
  • Drug: sumatriptan/naproxen sodium
    Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
    Other Name: Treximet
  • Drug: Placebo
    Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
  • Active Comparator: Treximet
    In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.
    Intervention: Drug: sumatriptan/naproxen sodium
  • Placebo Comparator: Placebo
    In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
23
November 2012
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

Subject

  • is male or female between the ages of 18-65. A female is eligible to enter and participate in this study if she is of: a.non-childbearing potential (i.e., physiologically incapable of becoming pregnant); or,b. child-bearing potential, has a negative pregnancy test (urine or serum) at Visit 2, and agrees to one of the following: Complete abstinence from intercourse from 2 weeks prior to administration of the investigational product, throughout the study, and for a time interval (5 days) after completion or premature discontinuation from the study to account for elimination of the investigational drug; subjects utilizing this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent when they present to the clinic for the final visit or, Female sterilization; or, Sterilization of male partner; or, Implants of levonorgestrel; or, Injectable progestogen; or, Oral contraceptive (combined or progestogen only); or, Any intrauterine device (IUD) with published data showing that the highest expected failure rate is less than 1% per year (not all IUDs meet this criterion); or, Spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a female diaphragm); or, Any other barrier methods (only if used in combination with any of the above acceptable methods); or, Any other methods with published data showing that the highest expected failure rate for that method is less than 1% per year.
  • is formally diagnosed with International Classification of Headache Disorders (ICHD) 5.2.2 chronic post traumatic headache
  • has >15 headache days per month in past 3 months
  • has headache that, if left untreated, would have at least 1 symptom of migraine (nausea, vomiting, photophobia, or phonophobia) or respond to a triptan or ergotamine-containing medication with at least 50% of headaches
  • is medically stable as determined by the Investigator
  • if taking a headache preventive medication, has been on a stabilized dosage for at least 30 days prior to screening.
  • if taking any concomitant medications, is on a stabilized dosage at the discretion of the investigator
  • has chronic headache history only after the traumatic brain injury (TBI)
  • is able to understand and communicate intelligibly with the study observer
  • is able to take oral medication, adhere to the medication regimens and perform study procedures
  • is able to read and comprehend written instructions and be willing to complete all procedures and assessments required by this protocol
  • is able to demonstrate the willingness to participate by signing and understanding an informed consent after full explanation of the study
  • has self-reported cognitive inefficiency or "brain-fog" during headache

Exclusion Criteria:

Subject

  • has a history of serotonin syndrome
  • has any medical condition that, in the opinion of the investigator, could alter the response to study medication or confound the results of the study
  • is female of childbearing potential not using adequate contraceptive measures
  • has history of retinal, basilar or hemiplegic migraine, cluster headache, or secondary headaches (such as due to infection, alterations of homeostasis, ear nose and throat (ENT) or psychiatric disorders, cranial or cervical disorders or neuralgias)
  • in the investigator's opinion, is likely to have unrecognized cardiovascular or cerebrovascular disease (based on history or the presence of risk factors including but not limited to, hypertension, hypercholesterolemia, smoker, obesity, diabetes, or family history of coronary artery disease)
  • has blood pressure ≥140/90 millimeters of mercury (mmHg) in 2 out of 3 BP measurements at screening or is taking any angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker
  • has a history of significant congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in this study
  • has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease or Raynaud's Syndrome, or signs/symptoms consistent with any of the above
  • has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold; or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening
  • has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study
  • has hypersensitivity, intolerance, or contraindication to the use of any triptan, nonsteroidal antiinflammatory drug (NSAID) or aspirin (including all sumatriptan and naproxen preparations) or has nasal polyps and asthma
  • is currently taking, or has taken in the previous three months, a migraine prophylactic medication containing methysergide; or is taking a migraine or menstrual migraine prophylactic medication that is not stabilized (i.e. start or change of dose within 30 days prior to screening)
  • has a recent history of regular use of opioids or barbiturates for treatment of their migraine headache and/or other non-migraine pain or any medication overuse that in the opinion of the investigator has exacerbated or contributed to the current headache pattern of the subject.
  • has taken, or plans to take, a monoamine oxidase inhibitor (MAOI), including herbal preparations containing St. John's Wort (Hypericum perforatum), anytime within the 2 weeks prior to screening through 2 weeks post final study treatment.
  • has history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent.
  • has evidence or history of any gastrointestinal surgery or GI ulceration or perforation in the past six months, gastrointestinal bleeding in the past year; or evidence or history of inflammatory bowel disease
  • is pregnant, actively trying to become pregnant, or breast feeding
  • has evidence of alcohol or substance abuse within the last year or any concurrent medical or psychiatric condition which, in the investigator's judgment, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicates participation in this clinical trial.
  • has participated in an investigational drug trial within the previous four weeks or plans to participate in another study at any time during this study.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01053507
114126
No
Cady, Roger, M.D.
Cady, Roger, M.D.
GlaxoSmithKline
Principal Investigator: Roger K Cady, MD Clinvest
Cady, Roger, M.D.
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP